StockTake: Alterity’s ATH434 shows US$2.4b potential for treating MSA

Host Tylah Tully looks at Alterity Therapeutics (ASX:ATH) and the highlighted multi billion dollar potential of its lead candidate for the rare neurodegenerative disease Multiple System Atrophy.

Watch the video for more. 

This video was developed in collaboration with Alterity Therapeutics, a Stockhead advertiser at the time of publishing.

This video does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.